| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
PPARγ
SDPC targets PPARγ (peroxisome proliferator-activated receptor gamma), a nuclear receptor that regulates lipid metabolism, glucose homeostasis, and inflammation. As a PPARγ activator, SDPC exerts anti-angiogenic effects. The compound's structure features an ester bond linking DHA at the sn-2 position of the phospholipid. By activating PPARγ, it modulates gene expression involved in angiogenesis and endothelial cell function. |
|---|---|
| ln Vitro |
In vitro studies demonstrate that SDPC significantly reduces the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs). It exerts anti-angiogenic effects through activation of PPARγ. In MTT assays, SDPC inhibits HUVEC proliferation with an IC50 of 331.8 μg/mL at 48 hours. Wound-healing assays confirm its inhibitory effects on cell migration. These activities make it a valuable tool for angiogenesis research.
|
| ln Vivo |
In vivo activity of SDPC is inferred from its anti-angiogenic mechanism as a PPARγ activator. By inhibiting endothelial cell proliferation, migration, and tube formation, the compound may reduce pathological angiogenesis in vivo. Detailed in vivo efficacy data from animal models, including tumor angiogenesis and retinopathy models, are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro receptor binding assay for SDPC involves measuring its activation of PPARγ. Transcriptional reporter assays using PPARγ-responsive luciferase constructs transfected into cells are commonly employed. Cells are treated with SDPC at various concentrations, and luciferase activity is measured to assess PPARγ activation. Standard protocols include appropriate positive controls such as rosiglitazone and vehicle controls.
|
| Cell Assay |
In vitro cell-based assays for SDPC are conducted using human umbilical vein endothelial cells (HUVECs). Cells are treated with the compound at various concentrations, and proliferation is measured using MTT or CCK-8 assays. Cell migration is assessed using wound-healing or transwell assays. Tube formation is evaluated on Matrigel-coated plates. PPARγ activation is confirmed by measuring downstream target gene expression by qPCR. Cytotoxicity is evaluated using standard cell viability assays.
|
| Animal Protocol |
In vivo animal studies for SDPC would typically be conducted using mouse models of angiogenesis-dependent diseases such as cancer, retinopathy, or wound healing. Animals would be administered the compound via appropriate routes, and angiogenesis would be assessed by measuring vessel density, tumor growth, or wound closure. PPARγ activation in tissues would be confirmed. However, detailed protocols and efficacy data are not available from the search results.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SDPC include a molecular weight of 834.16 and a molecular formula of C48H84NO8P. As a phospholipid containing DHA at the sn-2 position, it is a new generation omega-3 lipid. Detailed pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not extensively documented in the available literature. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for SDPC is limited. As a naturally occurring phospholipid, it is generally considered to have low toxicity. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
1-Octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol-3-phosphocholine is a phosphatidylcholine 40:6, wherein the acyl groups at positions 1 and 2 are octadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl, respectively. It is a mouse metabolite. Its function is related to octadecanoic acid and all-cis-docosahexaenoic acid (4,7,10,13,16,19-hexaenoic acid).
SDPC (DHA-PC; 18:0/22:6 PC) is a new generation omega-3 lipid with DHA at the sn-2 position. It exerts anti-angiogenic effects through PPARγ activation. It inhibits HUVEC proliferation (IC50 331.8 μg/mL), migration, and tube formation. It has MW 834.16 and formula C48H84NO8P. It is intended for research use only. |
| Molecular Formula |
C48H84NO8P
|
|---|---|
| Molecular Weight |
834.16
|
| Exact Mass |
833.593
|
| CAS # |
59403-52-0
|
| PubChem CID |
24778876
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
11.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
58
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
| InChi Key |
FAUYAENFVCNTAL-PFFNLMTBSA-N
|
| InChi Code |
InChI=1S/C48H84NO8P/c1-6-8-10-12-14-16-18-20-22-23-24-25-27-29-31-33-35-37-39-41-48(51)57-46(45-56-58(52,53)55-43-42-49(3,4)5)44-54-47(50)40-38-36-34-32-30-28-26-21-19-17-15-13-11-9-7-2/h8,10,14,16,20,22,24-25,29,31,35,37,46H,6-7,9,11-13,15,17-19,21,23,26-28,30,32-34,36,38-45H2,1-5H3/b10-8-,16-14-,22-20-,25-24-,31-29-,37-35-/t46-/m1/s1
|
| Chemical Name |
[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1988 mL | 5.9941 mL | 11.9881 mL | |
| 5 mM | 0.2398 mL | 1.1988 mL | 2.3976 mL | |
| 10 mM | 0.1199 mL | 0.5994 mL | 1.1988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
